CohBar Inc. (NASDAQ:CWBR) and VistaGen Therapeutics Inc. (NASDAQ:VTGN), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership of the two firms.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CohBar Inc.	N/A	0.00	14.35M	-0.35	0.00
VistaGen Therapeutics Inc.	N/A	0.00	20.02M	-0.94	0.00

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for CohBar Inc. and VistaGen Therapeutics Inc.

Profitability

Table 2 shows us the return on equity, net margins and return on assets of both businesses.

	Net Margins	Return on Equity	Return on Assets
CohBar Inc.	0.00%	-96.8%	-80.6%
VistaGen Therapeutics Inc.	0.00%	-328.5%	-187.7%

Volatility & Risk

CohBar Inc. has a 1.06 beta, while its volatility is 6.00% which is more volatile than Standard & Poor’s 500. Competitively, VistaGen Therapeutics Inc.’s 206.00% volatility makes it more volatile than Standard & Poor’s 500, because of the -1.06 beta.

Liquidity

CohBar Inc.’s Current Ratio is 33.2 while its Quick Ratio is 33.2. On the competitive side is, VistaGen Therapeutics Inc. which has a 6.5 Current Ratio and a 6.5 Quick Ratio. CohBar Inc. is better positioned to pay off short and long-term obligations compared to VistaGen Therapeutics Inc.

Insider & Institutional Ownership

The shares of both CohBar Inc. and VistaGen Therapeutics Inc. are owned by institutional investors at 9.6% and 11.6% respectively. Insiders owned roughly 4.5% of CohBar Inc.’s shares. Competitively, VistaGen Therapeutics Inc. has 2.47% of it’s share owned by insiders.

Performance

Here are the Week, Month, Quarter, Half Year, Year and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
CohBar Inc.	-12.47%	-9.37%	-24.31%	-61.17%	-22.17%	-27.97%
VistaGen Therapeutics Inc.	-1.67%	-14.49%	28.26%	24.65%	-12.81%	58.97%

For the past year CohBar Inc. has -27.97% weaker performance while VistaGen Therapeutics Inc. has 58.97% stronger performance.

Summary

On 5 of the 6 factors CohBar Inc. beats VistaGen Therapeutics Inc.

CohBar, Inc., a biotechnology company, engages in the research and development of mitochondria based therapeutics (MBTs) to treat various diseases associated with aging and metabolic dysfunction. Its lead MBT drug candidates include CB4209 and CB4211, which are in IND-enabling studies for the treatment of fatty liver disease, non-alcoholic steatohepatitis, obesity, and type 2 diabetes mellitus. The company is also developing Humanin, a mitochondrial-derived peptide to treat AlzheimerÂ’s disease, atherosclerosis, myocardial and cerebral ischemia, and type 2 diabetes mellitus; SHLP-6 for the treatment of cancer; and SHLP-2 to treat AlzheimerÂ’s disease and type 2 diabetes mellitus. CohBar, Inc. was founded in 2007 and is headquartered in Menlo Park, California.

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform to discover, rescue, develop, and commercialize new chemical entities (NCEs) for CNS and other diseases; and regenerative medicine involving hPSC-derived blood, cartilage, heart, and liver cells. In addition, the company develops CardioSafe 3D, an in vitro cardiac bioassay system for predicting human heart toxicity of small molecule NCEs. VistaGen Therapeutics, Inc. has licensing, sublicensing, and collaboration agreements with BlueRock Therapeutics, LP; U.S. National Institutes of Health; Cato Research Ltd.; and University Health Network. The company was founded in 1998 and is headquartered in South San Francisco, California.